Want to see SLDB full AI Analyst Report?

Solid Biosciences (SLDB) Price & Analysis

1,589 Followers

SLDB Stock Chart & Stats

$7.83

-$0.15(-1.88%)

At close: Jul 24 4:00 PM EDT

$7.83

-$0.15(-1.88%)

Day’s Range― - ―

52-Week Range$3.79 - $11.45

Previous CloseN/A

Volume1.09M

Average Volume (3M)2.23M

Market Cap

$948.94M

Enterprise Value$1.08K

Total Cash (Recent Filing)$377.68M

Total Debt (Recent Filing)$20.16M

Price to Earnings (P/E)―

Beta1.83

Next Earnings

Nov 11, 2026

EPS Estimate

-0.42

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.91

Shares Outstanding107,225,235

10 Day Avg. Volume1,056,120

30 Day Avg. Volume2,232,540

Financial Highlights & Ratios

PEG Ratio0.08

Price to Book (P/B)2.74

Price to Sales (P/S)0.00

P/FCF Ratio-3.13

Enterprise Value/Market Cap<0.01

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit>-0.01

Enterprise Value/Ebitda>-0.01

Forecast

1Y Price Target

$17.00

Price Target Upside117.11% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)-1.81

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage And Stronger Balance-sheet BufferA low absolute debt load and debt-to-equity near 0.05 provide durable financial flexibility for a clinical-stage biotech. This reduces insolvency and interest-service risk, extending runway against cash burn so R&D programs can continue while management pursues partnerships or non-debt funding.

Institutionalized Equity Financing CapacityAn amended shelf and consolidated ATM framework institutionalize access to public equity markets, creating a structural funding channel. For a pre-revenue developer this supports continuity of clinical programs, potential M&A or partnerships, and funding to reach key development milestones.

Focused Genetic-medicine Pipeline For DMDA concentrated focus on gene therapies for Duchenne muscular dystrophy and enabling platform capabilities aligns Solid with a clear, high-unmet-need market. Sustained technical focus builds domain expertise and potential competitive moats that can translate into durable therapeutic value if clinical programs advance.

Bears Say

No Commercial Revenue; Widening Net LossesZero reported commercial revenue and large, widening losses mean the firm's economics rely entirely on financing and high-risk clinical success. Persistent unprofitability erodes equity, limits strategic optionality, and makes long-term viability contingent on achieving clinical or regulatory breakthroughs.

Large And Worsening Operating Cash BurnSteep, deteriorating operating cash flow and negative free cash flow consume capital rapidly, forcing dependence on external financing. Sustained burn constrains the ability to pursue multiple programs, raises the chance of program delays or cuts, and increases financing frequency risk.

Dilution Risk From Repeated Equity FinancingsRecent ATM proceeds, a new $200M shelf registration, and approval enabling more shares institutionalize equity issuance as the primary funding route. Repeated dilution lowers per-share economics, can impair long-term shareholder returns, and signals ongoing dependence on capital markets absent de-risking milestones.

Solid Biosciences News

Solid Biosciences reports Q2 EPS (38c), consensus (47c)

Bo Cumbo, President and CEO of Solid Biosciences (SLDB), stated: “Our progress in the first half of 2026...

7d ago

SLDB

Solid Biosciences files automatic mixed securities shelf

17:01 EDT Solid Biosciences (SLDB) files automatic mixed securities shelf Published first on TheFly – the ultimate source...

7d ago

SLDB

Solid Biosciences: Buy Rating Reaffirmed on Advancing Duchenne and Friedreich’s Ataxia Programs, $25 Price Target Maintained

In a report released today, Arthur He CFA from H.C. Wainwright maintained a Buy rating on Solid Biosciences,...

4d ago

SLDB

Solid Biosciences: Advancing Gene Therapy Pipeline, Strong Cash Runway Support Buy Rating with Unchanged $14 Price Target

Citi analyst Yigal Nochomovitz reiterated a Buy rating on Solid Biosciences on August 7 and set a price...

4d ago

SLDB

Solid Biosciences Updates Shelf for $200 Million Offering

Solid Biosciences ( ($SLDB) ) has shared an update. Solid Biosciences Inc. on August 6, 2026 filed a...

7d ago

SLDB

Citizens biotech analysts hold an analyst/industry conference call

Biotech Analysts discuss Friedreich’s Ataxia developments from the patient community perspective (relevant companies LRMR SLDB BIIB PTCT LXEO...

1M ago

BIIB

DSGN

Solid Biosciences Shareholders Approve Directors and Share Increase

Solid Biosciences ( ($SLDB) ) just unveiled an update. At its June 10, 2026 annual meeting, Solid Biosciences...

2M ago

SLDB

Solid Biosciences price target raised to $25 from $20 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Solid Biosciences (SLDB) to $25 from $20 and keeps a...

2M ago

SLDB

Solid Biosciences price target lowered to $16 from $17 at Wedbush

Wedbush lowered the firm’s price target on Solid Biosciences (SLDB) to $16 from $17 and keeps an Outperform...

3M ago

SLDB

Solid Biosciences price target raised to $18 from $17 at Piper Sandler

Piper Sandler analyst Biren Amin raised the firm’s price target on Solid Biosciences (SLDB) to $18 from $17...

3M ago

SLDB

Solid Biosciences doses part participant in IMPACT DUCHENNE study

Solid Biosciences (SLDB) announced that the first participant has been dosed in IMPACT DUCHENNE, the company’s multi-country, placebo-controlled,...

3M ago

SLDB

Solid Biosciences receives orphan drug designation for SGT-003 from EC

Solid Biosciences (SLDB) announced that the European Commission, acting upon the positive opinion from the European Medicines Agency...

4M ago

SLDB

Solid Biosciences Adjusts Board Classes in Governance Move

An announcement from Solid Biosciences ( ($SLDB) ) is now available. Solid Biosciences Inc. announced changes to its...

4M ago

SLDB

Solid Biosciences price target raised to $12 from $11 at JPMorgan

JPMorgan raised the firm’s price target on Solid Biosciences (SLDB) to $12 from $11 and keeps an Overweight...

5M ago

SLDB

SLDB FAQ

What was Solid Biosciences’s price range in the past 12 months?

Solid Biosciences lowest stock price was $3.79 and its highest was $11.45 in the past 12 months.

What is Solid Biosciences’s market cap?

Solid Biosciences’s market cap is $948.94M.

When is Solid Biosciences’s upcoming earnings report date?

Solid Biosciences’s upcoming earnings report date is Nov 11, 2026 which is in 89 days.

How were Solid Biosciences’s earnings last quarter?

Solid Biosciences released its earnings results on Aug 06, 2026. The company reported -$0.38 earnings per share for the quarter, beating the consensus estimate of -$0.462 by $0.082.

Is Solid Biosciences overvalued?

According to Wall Street analysts Solid Biosciences’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Solid Biosciences pay dividends?

Solid Biosciences does not currently pay dividends.

What is Solid Biosciences’s EPS estimate?

Solid Biosciences’s EPS estimate is -0.42.

How many shares outstanding does Solid Biosciences have?

Solid Biosciences has 107,225,235 shares outstanding.

What happened to Solid Biosciences’s price movement after its last earnings report?

Solid Biosciences reported an EPS of -$0.38 in its last earnings report, beating expectations of -$0.462. Following the earnings report the stock price went down -3.674%.

Which hedge fund is a major shareholder of Solid Biosciences?

Currently, no hedge funds are holding shares in SLDB

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Solid Biosciences Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

22.97%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Solid Biosciences

Solid Biosciences (NASDAQ: SLDB) is a biotechnology company focused on developing genetic medicines for neuromuscular and cardiac diseases, with a primary focus on Duchenne muscular dystrophy (DMD). The company’s work centers on advancing therapeutic candidates (including next-generation gene therapy approaches) through research and clinical development, and it also engages in activities related to developing and applying enabling platforms and capabilities for genetic medicine.

Solid Biosciences (SLDB) Earnings & Revenues

Historic Earnings Reports

SLDB Stock 12 Month Forecast

Average Price Target

$17.00

▲(117.11% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","15":"$15","26":"$26","9.5":"$9.5","20.5":"$20.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$25.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":11,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$11.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9.5,15,20.5,26],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.06,9.363076923076923,10.666153846153847,11.96923076923077,13.272307692307692,14.575384615384614,15.878461538461536,17.18153846153846,18.48461538461538,19.787692307692303,21.090769230769226,22.39384615384615,23.696923076923074,{"y":25,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.06,8.747692307692308,9.435384615384615,10.123076923076923,10.810769230769232,11.498461538461537,12.186153846153847,12.873846153846154,13.561538461538461,14.249230769230769,14.936923076923076,15.624615384615385,16.31230769230769,{"y":17,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.06,8.286153846153846,8.512307692307692,8.73846153846154,8.964615384615385,9.19076923076923,9.416923076923077,9.643076923076924,9.86923076923077,10.095384615384615,10.321538461538461,10.547692307692309,10.773846153846154,{"y":11,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.83,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.43,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.87,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.39,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.21,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.64,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.43,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.2,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.38,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.13,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.19,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.2,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.06,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >